clinical trial · NCT00751075
Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692)
Organon and Co·phase3·completed·n = 981
Acute Rhinosinusitismometasone furoate nasal spray (MFNS)MFNSAmoxicillinPlacebo
brief summary
This study was conducted to compare the effectiveness and safety of mometasone nasal spray once daily or twice daily with amoxicillin or with placebo in treating the signs and symptoms of acute rhinosinusitis. Patients received mometasone nasal spray 2 sprays per nostril once daily, 2 sprays per nostril twice daily, amoxicillin 500 mg three times a day, or placebo three times a day. Patients on nasal spray were treated for 15 days and patients on amoxicillin or placebo were treated for 10 days. All patients were followed-up with a 14-day no-treatment observation period.
started
Dec 1, 2003
primary completion
May 6, 2004
completion
Jun 22, 2004
last updated
Aug 15, 2024
official title
Efficacy and Safety of 200 mcg QD or 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Amoxicillin vs Placebo as Primary Treatment of Subjects With Acute Rhinosinusitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol